New partnership to improve seed supplies of vital anti-malarial plant
Posted on 2 November 2011
At the Artemisinin Conference in Hanoi, the Centre for Novel Agricultural Products (CNAP), at the University of York, and East-West Seed announced a new partnership to ensure that high yielding seeds from improved varieties of Artemisia annua will rapidly be made available for global cultivation.
CNAP has partnered
with leading tropical seed company East-West Seed to produce Artemisia seeds in
commercial quantities. This new supply
of improved seed will help build up a robust supply chain for the production of
Artemisinin Combination Therapies (ACTs), the World Health Organisation
recommended treatment for malaria.
Through the
partnership, large-scale commercialization and distribution of the seeds to
Artemisia growers are expected in 2012, targeting 20% of the global Artemisia
cultivation acreage. Annual global
demand for ACTs is expected to increase beyond the current level of 250 million
treatments to up to 310 million by 2015 and the new high yielding seeds will
help achieve the strategic aims of universal coverage of ACTs and access to
treatments.
Past field trial
results demonstrate that all the newly available varieties will perform well in
various growing conditions and under diverse regional agricultural
practices. In the trials, plants have
been assessed for abundance of yield, robustness, and resistance to pests and
diseases.
This provides an excellent opportunity for the new Artemisia varieties
developed at York to make a real difference to the fight against malaria
Dianna Bowles
Bert van der Feltz,
VP Sales and Marketing, said ‘Through this new partnership with CNAP, East-West
Seed can count itself among the many organizations and individuals -- national
governments, donor foundations, research institutions, universities,
pharmaceutical companies and individual philanthropists – who are committed to
the elimination and eradication of malaria.’
Dianna Bowles, one of
the Co-Principal Investigators at CNAP said ‘I am delighted that we have
successfully partnered with East-West Seed. This provides an excellent opportunity for the new Artemisia varieties
developed at York to make a real difference to the fight against malaria.’
Ian Graham, the CNAP
Director and Co-Principal Investigator on the project, said ‘This partnership
with East-West Seed is excellent for the project and
demonstrates CNAP’s commitment to delivery as well as top quality research’.
Notes to editors:
- Contacts
in CNAP and East-West Seed: Caroline Calvert Tel:+44(0)1904 328763; Fax: +44(0)1904 328830; Email: caroline.calvert@york.ac.uk; Michael McDaniel Tel: +66-2-831-7788; Fax: +66-2-923-7794; Email: michael.mcdaniel@eastwestseed.com
- Malaria: Malaria is
one of the world’s most serious public health problems, claiming almost a million
lives every year and undermining development in some of the world’s poorest
countries. With new tools and increased
malaria funding, there is now real hope of making progress against this
disease. A massive scaling up of control
efforts is underway, and this includes increased use of ACTs to cure malaria.
- ACT: Artemisinin
Combination Therapies (ACTs) are currently the most effective cure for
malaria. Their active ingredient is
artemisinin, extracted from the plant Artemisia annua. Presently, quality Artemisia seeds are scarce
and the world’s total production of artemisinin is struggling to meet rising
global demand for ACTs. Commercialisation of the new seeds will help meet this additional
demand.
- The Centre
for Novel Agricultural Products (CNAP): CNAP is an award
winning strategic research centre based in the Biology Department at the
University of York. CNAP is dedicated to
realizing the potential of plants as renewable, low-cost factories that produce
high-value chemicals and biofuels.
Laboratory based discoveries are translated into practice in partnership
with industry.
- The CNAP
Artemisia Research Project: The Artemisia Research Project involves dedicated
teams of molecular biologists, plant breeders and horticulturalists led by
Professor Dianna Bowles and Professor Ian Graham. With funding from The Bill
& Melinda Gates Foundation, CNAP has been developing improved varieties of Artemisia annua to stabilise supplies of
artemisinin for the production of ACTs.
The latest genetic and analytical technologies have been used to
accelerate and enhance traditional plant breeding to generate the new, non-GM
improved varieties. In 2010 the researchers published the first genetic map of Artemisia annua.
- East-West
Seed: East-West
Seed is market leader for tropical vegetable seeds in Asia. Using the most
advanced technologies in vegetable plant breeding, East-West Seed creates value
for farmers by producing Better Seeds for Better Yield™. The company’s strategy is based on breeding
suitable varieties that allow farmers to be more productive, thereby
contributing to agricultural sustainability.
East-West seeds are planted in the fields of over 30 million farmers
worldwide. The company is Asia based
with over 2,000 employees and 12 R&D stations in 7 countries. We live and work in the markets we
serve.
- The
Artemsinin Conference: The Artemisinin Conference 2011 takes place in Hanoi, Vietnam, 2 - 3
November 2011. It is organized by FSC Development Services Ltd. This annual event
brings together the key players in the ACT supply chain, from those involved in
cultivating Artemisia annua through
to ACT manufacturers.
- Images and
video footage: Available on request from Caroline Calvert.
Contact details
Caroline Calvert (CNAP)
+44(0)1904 328763
or Michael McDaniel (East-West Seed)
+66-2-831-7788
Keep up to date
Subscribe to news feeds
Follow us on Twitter